Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282029 | 0.93 | CCR3 (0.58) | CCR3CNR2OPRM1OPRL1ALDH1A1 | |
| SCHEMBL3282930 | 0.88 | CCR3 (0.72) | CCR3ALDH1A1HTTNCOA1SMN1; SMN2 | |
| SCHEMBL3281208 | 0.87 | CCR3 (0.57) | CCR3ALDH1A1HTTNCOA1SMN1; SMN2 | |
| SCHEMBL3283117 | 0.87 | CCR3 (0.57) | CCR3ALDH1A1HTTNCOA1SMN1; SMN2 | |
| SCHEMBL3282341 | 0.87 | CCR3 (0.60) | CCR3ALDH1A1HTTNCOA1SMN1; SMN2 | |
| SCHEMBL3285359 | 0.86 | CCR3 (0.46) | CCR3CNR2OPRM1OPRL1EPHX2 | |
| SCHEMBL3282360 | 0.86 | CCR3 (0.62) | CCR3CNR2ALDH1A1HTTNCOA1 | |
| SCHEMBL3281236 | 0.86 | CCR3 (0.62) | CCR3ALDH1A1HTTNCOA1SMN1; SMN2 | |
| SCHEMBL3281313 | 0.85 | MTNR1A (0.56) | CCR3 | |
| SCHEMBL3282870 | 0.84 | HDAC1 (0.44) | CCR3CNR2OPRM1OPRL1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | claimed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | claimed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | claimed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | claimed |
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | SLC14A1, MAPT, UTS2R | CCR3 4014/4885CNR2 4654/4885OPRM1 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.